Want to see PBH full AI Analyst Report?
PBH Stock Chart & Stats
$50.40
$1.32(2.62%)
At close: 4:00 PM EDT
$50.40
$1.32(2.62%)
Day’s Range― - ―
52-Week Range$42.62 - $71.07
Previous Close$51.72
Volume439.54K
Average Volume (3M)783.95K
Market Cap
$2.43B
Enterprise Value$4.23K
Total Cash (Recent Filing)$89.13M
Total Debt (Recent Filing)$2.06B
Price to Earnings (P/E)14.3
Beta0.35
Next Earnings
Oct 29, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.59
Shares Outstanding47,374,523
10 Day Avg. Volume630,153
30 Day Avg. Volume783,950
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$72.00Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.58
Revenue Forecast (FY)$1.30B
Bulls Say, Bears Say
Bulls Say
Acquisition-led Portfolio ExpansionThe acquisitions expand PBH into nasal strips and therapeutic skincare while adding established brands and geographic reach. Their expected accretion and targeted low- to mid-30s% EBITDA margins could strengthen the portfolio over multiple years.
Strong Cash GenerationRobust free cash flow and high cash conversion provide funding for marketing, integration and debt reduction. Sustained cash generation gives PBH flexibility to absorb acquisition costs while improving financial resilience over the medium term.
Broad Branded Healthcare PortfolioExposure across multiple OTC and personal-care categories reduces dependence on any single product and supports repeat consumer purchases. Category breadth, brand equity and e-commerce growth can help preserve shelf presence and demand through changing consumer conditions.
Bears Say
Meaningful Leverage And Financing BurdenAcquisition financing materially increases obligations, while management expects roughly $100M of additional interest expense and leverage near 4x. This can constrain investment flexibility and make earnings more sensitive to integration results and cash-flow performance.
Supply-chain And Margin Execution RiskThe Clear Eyes disruption may require multiple quarters or years to stabilize, and transportation costs already pressured margins. Ongoing supply and integration issues could weaken brand availability, increase costs and delay realization of acquisition benefits.
Modest Underlying Organic GrowthAcquisitions are doing much of the work in the growth outlook, leaving the legacy portfolio with limited expected expansion. International weakness and dependence on retailer ordering patterns may make durable top-line growth harder to sustain without further deals.
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $42.62 and its highest was $71.07 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.43B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Oct 29, 2026 which is in 67 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Aug 06, 2026. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.894 by $0.086.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 1.07.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,374,523 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $0.98 in its last earnings report, beating expectations of $0.894. Following the earnings report the stock price went up 2.737%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.00 (42.86% Upside)
$72.00 (42.86% Upside)
Blogger Sentiment
Bearish
PBH Sentiment 60%
Sector Average 57%
Sector Average 57%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.13%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
PBH Company Deck
PBH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a broadly positive operational and financial start to fiscal '27: reported revenue and adjusted EBITDA grew, record adjusted free cash flow was delivered, and two strategic acquisitions (Breathe Right and LaCorium) were closed and are expected to meaningfully expand revenue and margins. Management acknowledged notable near-term challenges — most prominently Clear Eyes supply variability from Pillar5 integration, YoY gross margin pressure from transportation costs, international distributor timing, and elevated debt/interest costs — but provided specific remediation and integration plans, maintained organic growth guidance (1%–3%) and raised reported guidance driven by acquisitions. Given the strong cash flow, completed integration of Breathe Right, accretive acquisition profile, and maintained outlook despite manageable headwinds, the overall tone and expected trajectory are positive.View all PBH earnings summariesPBH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$72.00
▲(42.86% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Cardinal Health
―
Henry Schein
―
McKesson
―
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
1.38% Insiders
46.33% Mutual Funds
17.31% Other Institutional Investors
4.27% Public Companies and
Individual Investors









